Washington University/Siteman Cancer Center Lead Academic Site

华盛顿大学/斯特曼癌症中心领导学术网站

• 批准号: 10362574
• 负责人: NANCY L BARTLETT
• 金额: $ 130.7万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-05 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10362574
• 关键词: Acute leukemia; Address; American College of Radiology Imaging Network; Area; Cancer Center; Cancer Control; Clinical Research; Clinical Trials; Collaborations; Communication; Comprehensive Cancer Center; Cooperative Group Program; Correlative Study; Data; Development; Disease; Eastern Cooperative Oncology Group; Faculty; Fostering; Genomics; Goals; Gynecologic Oncology; Illinois; Institution; Lead; Leadership; Lymphoma; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of ovary; Medical Oncology; Mentors; Mentorship; Mission; Missouri; Modality; Molecular; Oncology; Patients; Physicians; Play; Positioning Attribute; Principal Investigator; Prognostic Marker; Protocols documentation; Quality of life; Radiation Oncology; Radiology Specialty; Recording of previous events; Rectal Cancer; Reporting; Research Personnel; Resistance; Site; Specialist; Therapeutic; Therapeutic Trials; Thoracic Oncology; Translational Research; Universities; Uterine Cancer; Washington; anticancer research; base; biobank; cancer therapy; control trial; design; diagnostic tool; experience; imaging program; imaging study; improved; leukemia/lymphoma; malignant breast neoplasm; member; metropolitan; mid-career faculty; molecular imaging; molecular pathology; novel; operation; pathology imaging; predictive marker; professor; programs; proteogenomics; rare cancer; response; sarcoma; translational scientist

Project Summary The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) NCTN Lead Academic Participating Site UG1 is to 1) foster scientific leadership and mentorship in the NCTN, 2) participate in the development of NCTN therapeutic, correlative, and cancer control trials, and 3) maintain strong accrual to clinical trials across multiple disease sites, including those that are molecularly driven and those for rare cancers. WU/SCC investigators have a long history of enthusiastic participation in the former cooperative group program and continue to play key roles in the current NCTN program, specifically the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 5 UG1 co-Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor, Medical Oncology), Benjamin Kozower, MD, MPH (Professor, Thoracic Oncology), David G. Mutch, MD (Professor, Gynecologic Oncology), Clifford Robinson, MD (Associate Professor, Radiation Oncology) and Barry A. Siegel, MD (Professor, Radiology). The WU/SCC senior leadership team is composed of three legacy members with extensive cooperative group and NCTN experience (Bartlett, Mutch and Siegel) and two new members (Robinson and Kozower) with experience in NCTN trial development. The entire leadership team is committed to providing guidance for an institution-wide NCTN UG1. WU/SCC has consistently demonstrated robust accrual to NCTN trials, accruing 848 patients between March 2014 and August 2017. During this same interval, 535 patients had biospecimens collected and 58 patients were accrued to advanced imaging studies. The strength of the WU/SCC genomics, proteogenomics, and molecular imaging programs in combination with the large institutional biorepositories position us to make significant and novel contributions to the scientific mission of the NCTN. WU/SCC investigators remain highly invested in NCTN translational and clinical research in AML, lymphoma, lung cancer, breast cancer, sarcoma, uterine cancer, molecular imaging, and radiation oncology. In addition, our large referral base and the substantial increase in new cancer cases seen at our center in the last 5 years will enhance our ability to accrue patients to nearly all disease site protocols, including rare tumors. This institution-wide UG1 will facilitate enhanced communication and collaboration among disease-site, translational, and modality specialists and improve our potential for contributions to the NCTN operation.

项目总结